Charlie's Holdings Q2 Revenue Surges 116% to $3.8M, But Cash Dwindles to $527K
CHUC sits 47% above its 52-week low of $0.15.
Summary
Charlie's Holdings reported Q2 2026 revenue of $3.8M, up 116% YoY, but cash fell to $527K and losses continued. A subsequent receivables sale and CEO transition add to the picture.
Key Events · Earnings and Guidance · CHUC
-
Revenue Surges 116%
Q2 2026 product revenue reached $3.8M, up 115.9% from $1.76M in Q2 2025, driven by SBX non-nicotine disposables.
-
Losses Persist
Net loss from continuing operations was $1.66M for Q2 and $2.71M for H1 2026, compared to net income of $4.92M and $3.66M in the prior-year periods (which included a $6.5M IP sale gain).
-
Cash Position Deteriorates
Cash fell to $527K as of June 30, 2026, from $1.32M at year-end 2025, despite $780K raised from share issuances.
-
Subsequent Receivables Sale
On July 23, 2026, the company sold $1.28M of future receivables for net proceeds of $990K, with weekly payments of $24,615 over ~52 weeks.
Analysis · CHUC · Life Sciences
Charlie's Holdings delivered explosive revenue growth in Q2 2026, with product revenue up 115.9% year-over-year to $3.8 million, driven by its SBX non-nicotine disposable vape line. However, the company remains deeply unprofitable, posting a net loss from continuing operations of $1.66 million for the quarter and $2.71 million for the first half. Cash has fallen to just $527,000, down from $1.32 million at year-end, despite raising $780,000 from share issuances. The company's going concern assessment hinges on continued revenue growth and potential asset sales, but the thin cash buffer and ongoing operating losses create near-term liquidity risk. A subsequent $1.28 million future receivables sale at a steep discount (netting $990,000) underscores the company's need for immediate working capital.
At the time of this filing, CHUC was trading at $0.22 on OTC in the Life Sciences sector, with a market capitalization of approximately $62M. The 52-week trading range was $0.15 to $0.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.